A compound chimeric antigen receptor strategy for targeting multiple myeloma

• Published in: Leukemia Vol. 32; no. 2; pp. 402 - 412
• Main Authors: Chen, K H, Wada, M, Pinz, K G, Liu, H, Shuai, X, Chen, X, Yan, L E, Petrov, J C, Salman, H, Senzel, L, Leung, E L H, Jiang, X, Ma, Y
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.02.2018; Nature Publishing Group
• Subjects: 13/106; 13/31; 631/250/1904; 631/250/232; 631/67/1990; 64/60; 692/699/67/1059/2325; 692/699/67/1059/602; 692/699/67/1990/804; Animal models; Anticancer properties; Antigens; Antitumor agents; Biocompatibility; Cancer Research; Care and treatment; Cell receptors; Chimeric antigen receptors; Critical Care Medicine; Cytotoxicity; Development and progression; Gene expression; Genetic aspects; Health aspects; Hematology; Intensive; Internal Medicine; Lymphocytes T; Medicine; Medicine & Public Health; Multiple myeloma; Oncology; Original; original-article; Populations; Receptors; T cell receptors; Toxicity
• ISSN: 0887-6924; 1476-5551
• DOI: 10.1038/leu.2017.302

Current clinical outcomes using chimeric-antigen receptors (CARs) against multiple myeloma show promise in the eradication of bulk disease. However, these anti-BCMA (CD269) CARs observe relapse as a common phenomenon after treatment due to the reemergence of either antigen-positive or -negative cells. Hence, the development of improvements in CAR design to target antigen loss and increase effector cell persistency represents a critical need. Here, we report on the anti-tumor activity of a CAR T-cell possessing two complete and independent CAR receptors against the multiple myeloma antigens BCMA and CS1. We determined that the resulting compound CAR (cCAR) T-cell possesses consistent, potent and directed cytotoxicity against each target antigen population. Using multiple mouse models of myeloma and mixed cell populations, we are further able to show superior in vivo survival by directed cytotoxicity against multiple populations compared to a single-expressing CAR T-cell. These findings indicate that compound targeting of BCMA and CS1 on myeloma cells can potentially be an effective strategy for augmenting the response against myeloma bulk disease and for initiation of broader coverage CAR therapy.